Intuitive Surgical Q4 EPS Beats by $0.26, Revenue Soars 18.8%, Cuts Growth Guidance to 13-15%
Intuitive Surgical reported Q4 EPS of $2.53, beating estimates by $0.26, and revenue of $2.87 billion, up 18.8% year-over-year. However, increased Chinese competition weighed on Japan reimbursement outlook, Ion system placements fell from 69 to 42, and 2026 da Vinci procedure growth guidance was cut to 13%-15%.
1. Institutional Stake Increases Highlight Broad Confidence
During the third quarter, Cullen Frost Bankers Inc. expanded its holding in Intuitive Surgical by 4.4%, acquiring an additional 3,450 shares to bring its total to 82,056 shares. This position, valued at nearly 37 million dollars at the end of the period, underscores growing institutional conviction. Commerzbank Aktiengesellschaft FI, Whittier Trust Co. of Nevada Inc., Whittier Trust Co., CIBC Asset Management Inc. and Robocap Asset Management Ltd. collectively boosted their stakes by between 1.3% and 27.2%, adding a total of over 16,900 shares. Institutional investors now control more than 83% of the float, signaling strong back-ing from major funds.
2. Analyst Upgrades Cement Moderate Buy Consensus
In recent weeks, multiple research houses have lifted their outlooks on the company’s shares. Truist Financial and Royal Bank of Canada each raised their targets by 30 dollars or more and reiterated buy or outperform ratings. BTIG Research and Leerink Partners maintained buy or outperform stances with upward revisions to their objectives, while HSBC increased its target by nearly 50 dollars. Among 26 analysts covering the stock, one issues a strong buy, fifteen favor buy, nine hold and one recommend sell, yielding a consensus rating of Moderate Buy and an average target north of 600 dollars.
3. Q4 Results Demonstrate Resilient Growth Dynamics
Intuitive Surgical reported fourth-quarter revenues of 2.87 billion dollars, up 18.8% year-over-year, driven by higher procedure volumes and service activity. Adjusted earnings per share of 2.53 exceeded consensus by 0.26. The firm’s net margin of 28.4% and return on equity of 15.2% highlight operational leverage. Looking ahead, management projects procedure growth of 13% to 15% for the current year, reflecting some caution in European capital markets and potential shifts in U.S. healthcare reimbursement dynamics.
4. Insider Dispositions Offer Mixed Signals
During the quarter, insiders sold a combined 55,714 shares, generating roughly 31.6 million dollars in proceeds. Senior vice president Mark Brosius reduced his holdings by 78% following a sale of 464 shares, while director Craig H. Barratt sold 750 shares. Despite these disposals, insiders retain alignment with long-term performance objectives, and total insider ownership remains below 1% of the outstanding shares, suggesting limited insider exposure to share-price fluctuations.